Drug Delivery

Dosing completed in phase III trials of Metformin, Ciprofloxacin

Published in Health and Medicine Week, December 8th, 2003

Depomed, Inc., (DMI) announced that it has completed the dosing of patients in both its second pivotal phase III clinical trial of once daily Metformin GR for the treatment of type II diabetes and in its pivotal phase III clinical trial of once daily Ciprofloxacin GR for the treatment of urinary tract infections.

Depomed also announced that it has been issued an additional patent on its proprietary, controlled-release Gastric Retention (GR) drug delivery system, on which both Metformin GR and Ciprofloxacin GR are based. Depomed anticipates completing data analyses and announcing the results of both phase III clinical trials in the first quarter of 2004, and filing New...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2003-12-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry